Business
Atavistik Bio Raises USD 40 Million Series B Extension, Totaling USD 160 Million Round
Atavistik Bio Closes USD 40 Million Series B Extension, Bringing Total Round to USD 160 Million
Salspera files to raise USD 85m via Nasdaq IPO for oncology biopharmaceutical platform
Salspera, Inc. (proposed Nasdaq: TKVA), a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company, filed a prospectus for an initial public...
Boehringer Ingelheim licenses preclinical immunometabolic program from Sitryx Therapeutics for over USD 500m
Boehringer Ingelheim (Ingelheim am Rhein, Germany) and Sitryx Therapeutics (Oxford, UK) announced on 26 February 2026 that Boehringer has acquired an...
VST BIO Corporation Closes Series A Financing With $45M Total Investment to Advance Stroke Therapy
VST BIO Corporation, a San Diego-headquartered biotechnology company developing therapeutics for acute ischemic stroke, has closed a Series A financing...
Asahi Kasei Acquires Aicuris Anti-infective Cures for EUR 780m to Bolster Infectious Disease Portfolio
The Asahi Kasei Aicuris acquisition, announced on February 26, 2026, will see the Tokyo-based conglomerate pay approximately EUR 780 million (USD 919...
Samsung Bioepis, Epis NexLab and G2GBIO partner on long-acting semaglutide using microsphere technology
Samsung Bioepis, Epis NexLab, and G2GBIO Enter Research Collaboration and License Agreement for Long-Acting Semaglutide
Vor Bio raises USD 75m in private placement led by TCGX
Vor Bio (Nasdaq: VOR), a Boston-based clinical-stage biotechnology company focused on autoimmune diseases, announced a USD 75 million private placement led...
PRISM BioLab and Receptor.AI collaborate on AI-guided drug discovery targeting protein-protein interactions
PRISM BioLab and Receptor.AI Enter Drug Discovery Collaboration to Target Protein-Protein Interactions with AI-Guided Platform
Tempus AI and Daiichi Sankyo collaborate on AI-driven biomarker discovery for antibody drug conjugate
Tempus AI and Daiichi Sankyo have entered a strategic collaboration to apply artificial intelligence and real-world data analytics to the clinical...
Otsuka Expands Psychiatric Portfolio With USD 1.225b Acquisition of Transcend Therapeutics
Otsuka Pharmaceutical Co., Ltd. has entered into an agreement to fully acquire Transcend Therapeutics, Inc., a clinical-stage biotechnology company...
OKYO Pharma raises USD 20m in underwritten public offering
UK-based OKYO Pharma Limited (Nasdaq: OKYO) announced the pricing of an underwritten public offering of ordinary shares for gross proceeds of approximately...
Theriva Biologics out-licenses SYN-020 to Rasayana Therapeutics in USD 38.3m worldwide deal
Theriva Biologics (NYSE American: TOVX), a clinical-stage company headquartered in Rockville, Maryland, announced an exclusive worldwide SYN-020 license...
Lyell Immunopharma raises USD 50m in additional equity private placement tranche
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage cell therapy company based in South San Francisco, California, announced the closing of an...
Rapport Therapeutics licenses RAP-219 to Tenacia Biotechnology in USD 328m. Greater China deal
Rapport Therapeutics Licenses RAP-219 to Tenacia Biotechnology for Greater China Development and Commercialization
Insilico Medicine and Lilly sign USD 2.75b multi-target AI drug discovery collaboration
Insilico Medicine's Pharma.AI platform is the centerpiece of a new multi-program drug discovery collaboration with Eli Lilly and Company (NYSE: LLY) that...
The AllSci Brief
Systematic R&D and deal news. Daily.